Cargando…

Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment

The overall survival for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) remains low, with little progress made over decades. Cisplatin, most frequently used for HNSCC treatment, activates mitochondria-dependent apoptosis through the BCL-2 family proteins. We have previously de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Britt, Erin L., Raman, Sarina, Leek, Kendall, Sheehy, Casey H., Kim, Sung W., Harada, Hisashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611623/ https://www.ncbi.nlm.nih.gov/pubmed/31276572 http://dx.doi.org/10.1371/journal.pone.0219398

Ejemplares similares

Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines
por: Lam, Lloyd T, et al.
Publicado: (2015)

ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
por: Yang, Xiaolan, et al.
Publicado: (2021)

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2014)

The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin
por: Geserick, P, et al.
Publicado: (2015)

p53‐independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells
por: Sharma, Kanika, et al.
Publicado: (2018)

ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer
por: Chen, Qiongrong, et al.
Publicado: (2015)

Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
por: Nakajima, W, et al.
Publicado: (2014)

Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
por: Yamaguchi, Ryuji, et al.
Publicado: (2011)

Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells
por: Yu, Rui, et al.
Publicado: (2021)

Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis
por: Yamaguchi, R, et al.
Publicado: (2011)

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X(L)–BAX interaction
por: Saleh, Tareq, et al.
Publicado: (2020)

KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
por: Wang, Guihua, et al.
Publicado: (2019)

Single Agent and Synergistic Activity of Maritoclax with ABT-263 in Nasopharyngeal Carcinoma (NPC) Cell Lines
por: Xiang, Benedict Lian Shi, et al.
Publicado: (2020)

Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis
por: Cooley, Joseph C., et al.
Publicado: (2023)

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199
por: García, Carolina Paola, et al.
Publicado: (2016)

ABT-263 Enhances Sensitivity to Metformin and 2-Deoxyglucose in Pediatric Glioma by Promoting Apoptotic Cell Death
por: Levesley, Jane, et al.
Publicado: (2013)

Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
por: Green, Maja M., et al.
Publicado: (2016)

Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells
por: Wang, Chihuei, et al.
Publicado: (2015)

Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis
por: Yang, Hao, et al.
Publicado: (2020)

ABT-263 enhanced bacterial phagocytosis of macrophages in aged mouse through Beclin-1-dependent autophagy
por: Zhang, Yu, et al.
Publicado: (2021)

Genetic variants of NOXA and MCL1 modify the risk of HPV16-associated squamous cell carcinoma of the head and neck
por: Zhou, Ziyuan, et al.
Publicado: (2012)

Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells
por: Airiau, Kelly, et al.
Publicado: (2015)

BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
por: Zhan, Yihong, et al.
Publicado: (2019)

The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice
por: Sharma, Anuj K., et al.
Publicado: (2020)

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2021)

ABT-263 exerts a protective effect on upper urinary tract damage by alleviating neurogenic bladder fibrosis
por: Wen, Yibo, et al.
Publicado: (2023)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice
por: Kakkola, L, et al.
Publicado: (2013)

Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor
por: Mühlenberg, Thomas, et al.
Publicado: (2015)

TXNIP induces growth arrest and enhances ABT263‐induced apoptosis in mixed‐lineage leukemia‐rearranged acute myeloid leukemia cells
por: Noura, Mina, et al.
Publicado: (2020)

JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
por: Wang, Huogang, et al.
Publicado: (2017)

Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells
por: Ohgino, Keiko, et al.
Publicado: (2020)

Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2022)

Clearance of senescent cells with ABT-263 improves biological functions of synovial mesenchymal stem cells from osteoarthritis patients
por: Miura, Yugo, et al.
Publicado: (2022)

EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263
por: Abdelgawad, Ibrahim Y., et al.
Publicado: (2022)

Treatment of advanced atherosclerotic mice with the senolytic agent ABT-263 is associated with reduced indices of plaque stability and increased mortality
por: Karnewar, Santosh, et al.
Publicado: (2023)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

Effects and Related Mechanisms of the Senolytic Agent ABT-263 on the Survival of Irradiated A549 and Ca9-22 Cancer Cells
por: Sato, Kota, et al.
Publicado: (2021)

Taking Advantage of the Senescence-Promoting Effect of Olaparib after X-ray and Proton Irradiation Using the Senolytic Drug, ABT-263
por: Huart, Camille, et al.
Publicado: (2022)

Upregulating Noxa by ER Stress, Celastrol Exerts Synergistic Anti-Cancer Activity in Combination with ABT-737 in Human Hepatocellular Carcinoma Cells
por: Zhu, Hong, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_iuvtgdqt5tsdt49s4djas7ss3f